Abstract: Embodiments of this application provide example holographic recording media, holographic polymer materials, methods for preparing holographic polymer materials, and display devices. An example holographic recording medium includes a first-order crosslinked network, a photoinitiator, and a second-order monomer. The first-order crosslinked network provides a mechanical support for the holographic recording medium. The second-order monomer includes a monomer with a free radical reactivity. The photoinitiator is used to initiate polymerization of the second-order monomer. The holographic recording medium includes at least one of an ester group (I), a urethane group (II), a carbamido group (III), an allophanate group (IV), or an amide group (V). Groups linked to the ester group (I), the urethane group (II), the carbamido group (III), the allophanate group (IV), and the amide group (V) are separately selected from at least one of the following: alkyl, alkoxy, alkenyl, or aryl.

Abstract: A polypeptide magnetic nanoparticle, comprising: a specific targeting polypeptide and a magnetic nanoparticle. The amino acid sequence of the specific targeting polypeptide is VRRDAPRFSMQGLDA-X, and the C-terminal X thereof is a sequence of 5 to 20 amino acids. The amino acid in the amino acid sequence of C-terminal X is selected from one or more of: C, G, and N. The polypeptide magnetic nanoparticle can be used for CTC detection and molecular typing of various cancer types, including esophageal cancer, liver cancer, lung cancer, stomach cancer, bladder cancer, skin cancer, melanoma, breast cancer, colorectal cancer, cervical cancer, etc. Biomarkers of CTC molecular typing include PD-L1, HER2, ER, PR, AR, EGFR, VEGFR, CXCR4, etc. The polypeptide magnetic nanoparticle is helpful for CTC detection and the qualitative and semiquantitative analysis of expression levels of biomarkers at CTC level, thereby performing precise therapy such as targeted individualized targeted therapy or immunotherapy on patients.